Drug intelligence / Profile preview

DN200434

Development stage: Preclinical
Lead developer: Daegu Gyeongbuk Medical Innovation Foundation
Modality: Small Molecules
Administration: Oral

Overview

DN200434 is an **orally available estrogen receptor-related gamma** (ERRγ) **inverse agonist**. It inhibits the proliferation and migration of vascular smooth muscle cells (VSMCs) and neointima formation by suppressing mitochondrial oxidative phosphorylation and mTORC1 activity, suggesting potential therapeutic use in occlusive vascular diseases and restenosis. DN200434 also enhances radioiodine avidity in anaplastic thyroid cancer cells, increasing their susceptibility to radioiodine therapy[1][2][4].

Targets

ESRRG (Estrogen-related receptor gamma)

Beyond the preview

Go deeper on DN200434.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DN200434.

Explore the full profile